Renin-Angiotensin System Inhibitors and Susceptibility to COVID-19

An observational study suggests that these drugs do not confer excess risk for COVID-19 hospitalization.

By now, clinicians generally are aware that angiotensin-converting–enzyme (ACE) inhibitors and angiotensin-receptor blockers (ARBs) have molecular and cellular effects relevant to COVID-19, with theoretical potential for either beneficial or harmful effects. NEJM Journal Watch recently reviewed several studies that focused mainly on whether these drugs affect the clinical course in patients with diagnosed COVID-19; so far, no clear benefits or harms have been documented (NEJM JW Gen Med Jun 1 2020 and N Engl J Med 2020 May 1; [e-pub]; NEJM JW Gen Med Jun 1 2020 and JAMA Cardiol 2020 Apr 23; [e-pub], Circ Res 2020 Apr 17; [e-pub], and MedRxiv 2020 Apr 11; [preprint]). Now, in a large study, investigators have examined whether taking ACE inhi…

Reviewing Author

Allan S. Brett, MD

Disclosures

Nothing to disclose

Allan S. Brett, MD

Disclosures

Nothing to disclose

Renin-Angiotensin System Inhibitors and Susceptibility to COVID-19

Topics

Reviewing Author